PatternsRadar
Sign in

MANKINDMankind Pharma Limited

NSEF&O
Full chart
2,500.00INR+21.00 (+0.85%)Close · 6 Oct 2026
30 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹1.03L CrMarket cap
49.9P/E (TTM)
54.3%Delivery

Filings & corporate actions

14 results filed
CSV
Next results · Q2 FY27
Expected 31 Oct 2026 – 6 Nov 2026
Estimate: filed 31–37 days after quarter end, last 3 times
Dividend
₹1.00 per share · last 8 Aug 2025
2026
  • 30 JulresultsResults · Q1 FY27 · consolidated and standalone-4.1%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+0.5%NSE
  • 19 MayresultsResults · Q4 FY26 · consolidated and standalone+3.7%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026+0.9%NSE
  • 3 FebresultsResults · Q3 FY26 · consolidated and standalone-3.4%NSE
  • 13 JanshareholdingShareholding · 31 Dec 2025-0.5%NSE

Reaction to results · all yearsrose on day 0 in 6 of 14 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2730 Jul 2026-4.1%-4.7%-7.5%6.5×
Q4 FY2619 May 2026+3.7%-2.9%-3.5%7.5×
Q3 FY263 Feb 2026-3.4%-3.5%+3.0%2.3×
Q2 FY266 Nov 2025-2.0%-1.8%-4.5%3.0×
Q1 FY2631 Jul 20250.0%-3.9%-0.9%0.7×
Q4 FY2521 May 2025-3.6%-2.7%-8.1%2.9×
Q3 FY2524 Jan 2025-4.9%-7.6%-10.9%3.0×
Q2 FY255 Nov 2024+1.3%-6.7%-4.7%6.6×
Q1 FY2531 Jul 2024-1.2%+2.2%+22.7%2.7×
Q4 FY2415 May 2024-4.5%-4.1%+2.3%8.4×
Q3 FY2431 Jan 2024+2.3%+12.5%+6.8%3.1×
Q2 FY2431 Oct 2023+0.1%+5.9%+9.0%2.3×
Q1 FY242 Aug 2023+9.1%+5.9%-1.3%5.9×
Q4 FY2331 May 2023+2.6%+7.1%+25.5%—
Average-0.3%-0.3%+2.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+12.9%
Profit YoY+29.1%
Interest cost YoY-1.8%
Revenue QoQ+17.1%
Profit QoQ+2.6%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+17.6%—————
Profit+1.9%—————

Key data

CSV
Open2,481.00
Day range2,464.50 – 2,508.90
52-week range1,909.70 – 2,642.00
From 52w high-5.4%
RSI (14)57.3
ATR (14)62.95
Volume2.98L
Avg volume (20D)5.73L
Rel volume0.52×
Volatility (1Y)26.3%
Turnover₹74.4Cr
SMA 50 / 2002,415.63 / 2,297.09

Delivery percentage

Latest · 6 Oct 202654.3%
20-day avg55.6%
1-year avg55.8%
Percentile (own history)39th
Range7.5–93.9%
Sessions848

Over the last 20 sessions MANKIND settled 55.6% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 55.8%. The latest session ranks higher than 39% of the 848 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+0.85%+2.64%+5.54%-1.08%+25.09%+0.69%

Valuation

CSV
Market cap₹1.03L Cr
P/E (TTM)49.9
EPS (TTM)50.06
Shares outstanding41.30Cr
Listed9 May 2023

Ownership

CSV
Promoter72.63%
Promoter Δ QoQ-0.03 pp
Public27.37%
FII9.45%
DII15.39%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)3,697.23,567.23,442.94,030.6
YoY chg+20.2%+10.4%+11.8%+12.9%
Net profit (₹ Cr)520.2413.9559.4574.1
YoY chg-21.1%+7.6%+31.7%+29.1%
Net margin14.1%11.6%16.2%14.2%
EPS12.389.8913.4113.74

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 72.63% · public 27.37%
4 May 2023: promoter 76.50%30 Jun 2023: promoter 76.50%30 Sept 2023: promoter 76.50%31 Dec 2023: promoter 76.50%31 Mar 2024: promoter 74.88%30 Jun 2024: promoter 74.87%30 Sept 2024: promoter 74.87%20 Dec 2024: promoter 72.71%31 Dec 2024: promoter 72.71%31 Mar 2025: promoter 72.70%30 Jun 2025: promoter 72.68%30 Sept 2025: promoter 72.67%31 Dec 2025: promoter 72.66%31 Mar 2026: promoter 72.66%30 Jun 2026: promoter 72.63%
2023-052026-06
  • Promoter
  • Public and others
Promoter
72.63%
Public
27.37%
Promoter change
-0.03 pp
Filed
21 Jul 2026
FII
9.45%
DII
15.39%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations2,708.12,607.02,441.12,893.43,076.53,230.03,079.43,570.43,697.23,567.23,442.94,030.6
Other income60.070.192.1100.6109.477.3251.379.991.972.8114.345.0
Total income2,768.12,677.12,533.22,994.03,185.93,307.33,330.73,650.23,789.03,640.03,557.24,075.6
Total expenses2,130.62,119.41,964.12,330.32,339.22,813.42,817.63,112.93,167.33,027.62,877.93,310.1
└ Finance costs8.69.29.410.97.1220.9190.5170.7169.7157.2141.8110.0
└ Depreciation96.5109.7104.7107.7105.6192.3230.9218.7221.8222.6223.1225.7
Profit before tax637.5557.7569.2663.7846.8493.9513.1537.3621.7505.8656.2765.5
Tax expense129.8102.595.0124.6190.4112.886.495.9103.895.199.8195.4
Net profit511.2459.8476.6543.1658.9384.5424.7444.6520.2413.9559.4574.1
EPS12.5111.3311.7613.3916.319.4510.1910.6212.399.9013.4413.76
Net margin18.88%17.64%19.52%18.77%21.42%11.90%13.79%12.45%14.07%11.60%16.25%14.24%
PBT margin23.54%21.39%23.32%22.94%27.52%15.29%16.66%15.05%16.82%14.18%19.06%18.99%
Tax rate20.36%18.38%16.69%18.77%22.49%22.84%16.85%17.84%16.70%18.81%15.20%25.52%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 30 Jul 2026.

MANKIND at a glance

  • MANKIND closed at ₹2,500 on 6 Oct 2026, +0.85% on the day, +0.7% over one year, 5.4% below its 52-week high of ₹2,642.
  • Delivery was 54.3% of traded quantity on 6 Oct 2026, the 39th percentile of its own 848 sessions with a reading (20-session average 55.6%, 1-year average 55.8%).
  • Market capitalisation is ₹1.03 lakh crore at a trailing P/E of 49.9 (trailing EPS ₹50.06).
  • Q1 FY27 results (consolidated, filed 30 Jul 2026): revenue ₹4,031 crore (+12.9% year on year), net profit ₹574 crore (+29.1%); the price moved -4.1% on the first session after.
  • Promoters held 72.63% at 30 Jun 2026, down 0.03 percentage points on the previous filing.
  • Q2 FY27 results are expected between 31 Oct 2026 and 6 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE634S01028
SeriesEQ
Listed9 May 2023
History from9 May 2023
Sessions848
Turnover rank#225

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE